This article reports on comprehensive genomic profiling of thymic epithelial tumors in the setting of advanced disease, identifying clinically-relevant genomic alterations in the KIT, PI3K, CDKN2A/B, or NTRK genes, which suggests potential precision medicine approaches using targeted agents. This evidence concerns the gene KIT and thymic epithelial neoplasm.